



ELSEVIER

Advanced Drug Delivery Reviews 39 (1999) 117–151

advanced
drug delivery
reviews

www.elsevier.com/locate/drugdeliv

Development and optimization of anti-HIV nucleoside analogs and prodrugs:

A review of their cellular pharmacology, structure-activity relationships and pharmacokinetics

Xiaolei Tan, Chung K. Chu, F. Douglas Boudinot*

Department of Pharmaceutical and Biomedical Sciences, University of Georgia College of Pharmacy, Athens, GA 30602-2352, USA

Received 5 October 1998; received in revised form 22 January 1999; accepted 3 February 1999

Abstract

Significant improvements in antiviral therapy have been realized over the past 10 years. Numerous nucleoside analogs, as well as prodrugs of active compounds, have been synthesized and tested for anti-HIV activity. In addition to the five nucleoside analogs currently used clinically for the treatment of HIV infection, a broad spectrum of anti-HIV nucleoside analogs (including 2',3'-dideoxynucleoside analogs, oxathiolanyl 2',3'-dideoxynucleoside analogs, dioxolanyl 2',3'-dideoxynucleoside analogs, carbocyclic 2',3'-dideoxynucleoside analogs and acyclic nucleoside analogs) and their prodrugs (including ester prodrugs, phospholipid prodrugs, dihydropyridine prodrugs, pronucleotides and dinucleotide analogs), targeted at HIV reverse transcriptase, are reviewed with focus on structure-activity relationships, cellular pharmacology and pharmacokinetics. Several of these anti-viral agents show promise in the treatment of AIDS. © 1999 Elsevier Science B.V. All rights reserved.

Keywords: Anti-HIV; Reverse transcriptase; 2',3'-Dideoxynucleoside analog; Nucleotide analog; Prodrug; Cellular pharmacology; Pharmacokinetics

Contents

1. Introduction	118
2. 2',3'-Dideoxynucleoside analogs	120
2.1. Structure-activity relationships	120
2.2. Thymidine (T) analogs	121
2.2.1. Cellular pharmacology	121
2.2.2. Pharmacokinetics	122
2.3. 2'-Deoxyuridine (dU) analogs	123
2.3.1. Cellular pharmacology	123
2.3.2. Pharmacokinetics	124
2.4. 2'-Deoxycytidine (dC) analogs	124

*Corresponding author. Tel.: +1-706-542-5335; fax: +1-706-542-5252.

E-mail address: boudinot@rx.uga.edu (F.D. Boudinot)

0169-409X/99/\$ – see front matter © 1999 Elsevier Science B.V. All rights reserved.
PII: S0169-409X(99)00023-X

Columbia Ex. 2088
Illumina, Inc. v. The Trustees
of Columbia University in the
City of New York
IPR2020-00988, -01065,
-01177, -01125, -01323

2.4.1. Cellular pharmacology.....	125
2.4.2. Pharmacokinetics	125
2.5. 2'-Deoxyadenosine (dA) and 2'-deoxyinosine (dI) analogs.....	125
2.5.1. Cellular pharmacology.....	125
2.5.2. Pharmacokinetics	127
3. Oxathiolanyl 2',3'-dideoxynucleoside analogs	127
3.1. Structure-activity relationships	127
3.2. Cellular pharmacology	128
3.3. Pharmacokinetics	128
4. Dioxolanyl 2',3'-dideoxynucleoside analogs	129
4.1. Structure-activity relationships	129
4.2. Cellular pharmacology	130
4.3. Pharmacokinetics	130
5. Carbocyclic 2',3'-dideoxynucleoside analogs	131
5.1. Structure-activity relationships	131
5.2. Cellular pharmacology	131
5.3. Pharmacokinetics	132
6. Acyclic nucleoside analogs	132
6.1. Structure-activity relationships	132
6.2. Cellular pharmacology	134
6.3. Pharmacokinetics	135
7. Ester prodrugs of 2',3'-dideoxynucleoside analogs	135
8. Phospholipid prodrugs of 2',3'-dideoxynucleoside analogs	135
8.1. Rationale for prodrug design	135
8.2. Cellular pharmacology	136
8.3. Pharmacokinetics	136
9. Dihydropyridine prodrugs of 2',3'-dideoxynucleoside analogs	136
9.1. Rationale for prodrug design	136
9.2. Cellular pharmacology	137
9.3. Pharmacokinetics	137
10. Pronucleotides: phosphatidyl 2',3'-dideoxynucleoside analogs	137
10.1. Rationale for prodrug design	137
10.2. Structure-activity relationships	138
10.3. Cellular pharmacology.....	138
10.4. Pharmacokinetics	139
11. Dinucleotide analogs	140
11.1. Rationale for prodrug design	140
11.2. Structure-activity relationships	140
12. Other pronucleotide approaches.....	141
13. Conclusions	141
References	141

1. Introduction

In combating acquired immunodeficiency syndrome (AIDS) and AIDS related complex (ARC), the search for therapeutic agents possessing activity against human immunodeficiency virus (HIV) has yielded a number of compounds demonstrating potent and selective antiviral activity. Human immunodeficiency virus reverse transcriptase (HIV-RT) remains a primary target for the treatment of HIV infection [1]. As HIV-RT inhibitors, five anti-HIV

nucleoside analogs have been approved by Food and Drug Administration (FDA) and are currently used clinically. These anti-HIV nucleoside analogs include zidovudine (AZT), didanosine (ddI), zalcitabine (ddC), stavudine (d4T), and lamivudine (3TC). Except for 3TC, which has a β -L-configuration, these nucleoside analogs have β -D-configurations similar to natural nucleosides.

The active antiretroviral form of a nucleoside analog is its triphosphate anabolite. By sharing the anabolic pathway of the naturally occurring nu-

cleosides, antiviral nucleoside analogs are phosphorylated to the corresponding mono-, di-, and triphosphates. Phosphorylation of nucleosides is catalyzed by cellular kinases as illustrated in Fig. 1. Although the efficiency of the phosphorylation of nucleoside analogs is generally lower than that of the naturally occurring nucleoside, the potent and selective anti-HIV activity of the nucleoside analog resides in strong inhibition of HIV-RT with relatively little effect on cellular polymerases exerted by the nucleoside-triphosphate. Once incorporated into the growing proviral DNA chain, nucleoside analogs terminate the viral DNA elongation owing to a lack of the 3'-OH. While the mechanism of antiviral

activity of nucleoside analogs may ultimately be the same, it should be noted that each compound has its own distinct metabolic and pharmacological properties. Besides the inhibition of HIV-RT, the effect of triphosphates of nucleoside analogs on cellular polymerases (pol α , β , δ , γ and ϵ) are also important to the understanding of the potential mechanisms involved in *in vitro* and *in vivo* activity and toxicity. Pol α , which is the main polymerase responsible for cellular DNA synthesis, is not inhibited by all FDA-approved nucleoside analogs.

A number of cell lines have been employed to investigate the *in vitro* anti-HIV activity and cytotoxicity of the nucleoside analogs, including human




Fig. 1. The intracellular phosphorylation pathways of FDA-approved nucleoside analogs.

T-cell lines such as MT-2, MT-4, H9, CEM, and ATH8, human peripheral blood mononuclear (PBM) cells, human peripheral blood lymphocytes (PBL), and murine C3H cells. The antiviral activity of nucleoside analogs depends critically on cellular kinases for the metabolic steps to produce the 5'-triphosphate. It is, therefore, not surprising that a compound's activity may vary to some extent with the type of cell line and the phase in the cell cycle, since the occurrence and the relative amounts of these kinases vary under different circumstances [2,3]. Based on the phosphorylation profiles, AZT and d4T are considered as cell-activation-dependent nucleoside analogs, while ddI, ddC and 3TC are classified as cell-activation-independent nucleoside analogs [4].

Myelosuppressive effects such as neutropenia and anemia are the main clinical adverse effects associated with AZT [5,6]. Nucleoside analogs are evaluated for hematological toxicity by inhibition of *in vitro* colony formation of human hematopoietic progenitors CFU-granulocyte (CFU-G) and burst-forming unit-erythroid (CFU-E) in bone marrow cells. Peripheral neuropathy is the primary adverse effect associated with ddI, ddC and d4T [7,8]. The decreased mitochondrial DNA (mtDNA) synthesis caused by nucleoside analogs is monitored as it is proposed to be related to delayed cytotoxicity *in vitro* and *in vivo* side effects of these compounds.

Unlike the natural nucleosides entering cells via facilitated transporters, anti-HIV nucleoside analogs permeate into cells by either simple diffusion or by a combination of simple diffusion and nucleoside/nucleobase carrier-mediated transportation [9,10]. Generally, *in vivo* nucleoside analogs are extensively distributed throughout the body but with limited penetration into the central nervous systems (CNS); they are rather rapidly cleared from the systemic circulation with apparent half-lives usually less than 3 h. Severe adverse effects and drug resistance are frequently observed clinically. Efforts have therefore been continuously made to develop and optimize nucleoside analogs. In addition to rigorous searches for new compounds with increased anti-HIV potency and selectivity, novel prodrug approaches have also been extensively investigated to improve the therapeutic characteristics of the drugs. Prodrugs are designed to increase exposure of anti-HIV nucleoside

analogs to the CNS and to target delivery of the drugs to the lymphatic system. The lymphatic system and CNS serve as reservoirs for HIV.

This current review is intended to give an overview of the field of nucleoside analogs and their prodrugs, with special focuses on the structure-activity relationships, cellular pharmacology and pharmacokinetics of the representative compounds.

2. 2',3'-Dideoxynucleoside analogs

2.1. Structure-activity relationships

2',3'-Dideoxynucleoside analogs (dT, ddC, ddA, ddI and ddG) except for ddU have anti-HIV activity in ATH8 cell cultures to various extents [11]. In ATH8 cells, 3'-azido (AZT) or 3'-fluoro substitution (FLT) or 2',3'-didehydro (d4T) modification greatly potentiates the anti-HIV activity of dT. On the other hand, 3'-fluoro substitution (FLC) or 2',3'-didehydro (Fd4C) modification decreases the anti-HIV activity of ddC. Similarly, 3'-azido (AZdA) substitution or 2',3'-didehydro (d4A) modification decreases the anti-HIV activity of ddA and increases its cytotoxicity [12]. In MT-4 and CH3 cells, 3'-azido (AZdU) or 3'-fluoro (FddU) substitution significantly increases the anti-HIV activity of ddU [13]. In MT-4 cells, 3'-azido (AZdG) or 3'-fluoro (FddG) substitution increases the anti-HIV activity of ddG. 2,6-Diaminopurine 2',3'-dideoxyribose (ddDAPR), AZddDAPR and FddDAPR have higher anti-HIV activity than ddG. However, AZddDAPR is also one of the most cytotoxic nucleoside analogs [14]. 2',3'-Didehydro (d4G) modification of ddG severely increases the cytotoxicity [15]. In H9 cells, 2'-'up' fluoro-substitution abolishes the anti-HIV activity of AZT, FLT and d4T, and decreases that of ddC [16,17]. 2'-Azido-modification of dideoxypyrimidine analogs do not possess any anti-HIV activity [18]. In MT-4 cells, 5'-isocyano-modification annihilates the anti-HIV activity of dT, AZT and AZdU [19]. In MT-4 cells, 5'-*O*-phosphonomethylation abolishes the anti-HIV activity of dT and ddC, and decreases that of FLT and AZT [20]. In CEM cells, selected 5-halo-6-alkoxy (or azido)-derivatives of AZT and FLT show equipotency against HIV [21,22].

2-Chloro-modification substantially decreases the

anti-HIV activity of ddA and d4A [23]. In MT-4 cells, 5-chloro-derivative of FddU (FddCIU) and AZdU (AZdCIU) have significantly higher selectivity than that of FddU and AZdU [24,25]. 5-Chloro derivatives of FddC, AZdC, d4C and ddC result in reduced cytotoxicity with slightly reduced anti-HIV activity [26]. 6-Halo-2',3'-dideoxypurine ribofuranosides have potent anti-HIV activity in various cells [27].

In CEM cells, β -L-ddC and β -L-FddC have potent anti-HIV and HBV activity with little inhibition of mtDNA synthesis, compared to β -D-ddC (natural configuration) [28]. Relative to d4C, β -L-Fd4C has more potent anti-HIV activity and less cytotoxicity, while β -L-d4C has comparable anti-HIV potency and cytotoxicity; β -L-Fd4C and β -L-d4C have little effect on mtDNA synthesis [29]. Among the isomeric dideoxynucleoside analogs, 4(S)-(6-amino-9H-purin-9-yl)tetrahydro-2(S)-furanmethanol (isoddA) and isoddG are potent anti-HIV activity in various cell cultures and low cytotoxicity [30].

2.2. Thymidine (T) analogs

The structures of thymidine and the antiviral thymidine analogs dT, AZT, FLT and d4T are shown in Fig. 2. The cellular kinases responsible for the phosphorylation of thymidine analogs are thymidine kinase (TK), thymidylate kinase (TmpK), and nucleoside diphosphate (NDP) kinase, which, respectively, mediate the metabolism to the mono-, di- and triphosphate anabolites. In this category, AZT and d4T are FDA approved anti-HIV drugs. FLT was tested in clinical trials without success owing to severe toxicity at doses required for anti-HIV efficacy.

2.2.1. Cellular pharmacology

Zidovudine has potent and selective anti-HIV activity in various human cell cultures [31,32]. AZT is phosphorylated to its monophosphate (AZTMP), diphosphate (AZTDP) and triphosphate (AZTTP) anabolites by TK, TmpK and NDP kinase, respec-




Fig. 2. Thymidine (T) and its analogs.

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.